Astec LifeSciences share price & results
- Sept 2026
- Sept 2026
Godrej-owned manufacturer of agrochemical actives, formulations and CDMO for global crop-protection firms.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 72.0 | −2.7% YoY | Quarterly, as filed | Quarter to Sept 2026 | Revenue from operations as filed. |
| Operating margin | -27.0 | −18.0 pts YoY | Operating profit / revenue | Quarter to Sept 2026 | For the quarter; a change is in percentage points. |
| Net profit | -37.0 | Quarterly, as filed | Quarter to Sept 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Return on equity | -23.35 | +20.0 pts | Trailing twelve months | TTM to Sept 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -19.16 | −12.9 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 16.09 | +34.4 pts | Trailing twelve months | TTM to Sept 2026 | Revenue change against the same period one year earlier. |
Price
Performance −3.7% 1Y
1Y: ₹668.25 on 24 Oct 2025 → ₹643.5. High ₹918.75 (25 Nov 2025), low ₹521.85 (23 Mar 2026).
- Previous close
- ₹652.85
- Market cap
- ₹1.5k Cr
- 52-week range
- ₹521.85 – ₹918.75
- One year
- −2.48%
- Return on equity (TTM to Sept 2026)
- -23.35%
Overview
- Symbol
- NSE:ASTEC
- Sector
- Chemicals
- Industry
- Commodities
- Exchange
- NSE
- Currency
- INR
What Astec LifeSciences Limited does
Based on the company's own presentations, annual report and earnings calls.
Astec LifeSciences manufactures agrochemical active ingredients (technicals), bulk formulations and intermediates, using multi-step synthesis to handle complex chemical reactions. It sells through two business lines: an Enterprise business selling its own technicals/formulations to domestic and export customers, and a Contract Development and Manufacturing (CDMO) business that makes agrochemical products on contract for global crop-protection innovators. It holds a leadership position in triazole fungicides in India and globally, and is a majority-owned subsidiary of Godrej Agrovet Limited (part of the Godrej Group).
Segments
- Agrochemicals
- Manufacturing plants
- 4 multipurpose, multi-product plants, all in Mahad, Maharashtra
- R&D centres
- 1 (Adi Godrej Center for Chemical Research & Development, Rabale, Maharashtra)
- Export countries
- 18 countries including USA, Europe, West Asia, Southeast Asia, Latin America and Africa
- Market position
- Leader in triazole fungicides, in India and globally
- Regular employees
- 554
- Dedicated facility
- Herbicide manufacturing facility with high-potency blocks and zero-liquid-discharge design, commissioned FY24-25 for CDMO business
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −54% (quarter to sept 2026 against sept 2025).
| Line item | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 94 | 120 | 91 | 74 | 125 | 159 | 84 | 72 |
| Expenses | 100 | 114 | 102 | 80 | 121 | 149 | 84 | 92 |
| Operating profit | -6 | 6 | -11 | -7 | 4 | 9 | -1 | -20 |
| Operating margin | −6.0% | 4.6% | −12.0% | −9.0% | 3.2% | 6.0% | −0.8% | −27.0% |
| Other income | 2 | 1 | 0 | 1 | -1 | 3 | 1 | 1 |
| Interest | 10 | 10 | 11 | 8 | 7 | 8 | 8 | 7 |
| Depreciation | 11 | 12 | 12 | 10 | 11 | 12 | 11 | 11 |
| Profit before tax | -25 | -16 | -33 | -24 | -16 | -8 | -19 | -37 |
| Tax rate | 60.0% | 3.0% | 0.0% | 0.0% | 0.0% | −2.0% | 0.0% | 0.0% |
| Net profit | -40 | -16 | -33 | -24 | -16 | -8 | -19 | -37 |
| EPS (₹ per share) | -18.04 | -7.19 | -14.76 | -10.97 | -7.06 | -3.49 | -8.41 | -16.80 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 628 | 459 | 382 | 449 |
| Expenses | 552 | 464 | 448 | 452 |
| Operating profit | 75 | -5 | -66 | -5 |
| Other income | 14 | 6 | 6 | 3 |
| Interest | 21 | 25 | 36 | 34 |
| Depreciation | 34 | 36 | 43 | 45 |
| Profit before tax | 35 | -62 | -142 | -81 |
| Net profit | 25 | -46 | -135 | -81 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 | Sept 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 20 | 20 | 20 | 22 | 22 | 22 |
| Reserves | 399 | 349 | 214 | 392 | 368 | 312 |
| Borrowings | 341 | 494 | 555 | 367 | 449 | 331 |
| Other liabilities | 219 | 111 | 92 | 102 | 102 | 129 |
| Total liabilities | 979 | 974 | 880 | 883 | 941 | 794 |
| Fixed assets | 318 | 386 | 499 | 500 | 459 | 457 |
| Capital work in progress | 127 | 165 | 21 | 0 | 20 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 533 | 423 | 360 | 383 | 462 | 335 |
| Total assets | 979 | 974 | 880 | 883 | 941 | 794 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | -8 | 23 | 74 | 10 | -8 | -81 |
| Cash from investing | -73 | -104 | -112 | -135 | -15 | -4 |
| Cash from financing | 81 | 80 | 38 | 125 | 24 | 94 |
| Net cash flow | 0 | 0 | 0 | 0 | 0 | 9 |
| Free cash flow | -111 | -80 | -42 | -125 | -24 | -85 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 123 | 148 | 90 | 135 | 141 | 202 |
| Inventory days | 113 | 176 | 268 | 224 | 196 | 169 |
| Days payable | 137 | 180 | 161 | 102 | 100 | 107 |
| Cash conversion cycle | 99 | 145 | 197 | 256 | 237 | 263 |
| Working capital days | 4 | 12 | -17 | -1 | -26 | -56 |
| Return on capital employed | 22.0% | 22.0% | 8.0% | −4.0% | −13.0% | −5.0% |
| Dividend payout | 5.0% | 3.0% | 12.0% | 0.0% | 0.0% | 0.0% |
Where revenue comes from
The businesses behind the company’s reported revenue.
Outside India contributes 68.4% of reported segment revenue.
Year ended 31 Mar 2025 · Consolidated
- Outside India 68.4%
₹258.55 crore
- Within India 31.6%
₹119.60 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| Outside India | 258.55 | 68.4% |
| Within India | 119.60 | 31.6% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
How these numbers add up
- Total segment revenue
- ₹378.15 crore
- Intersegment adjustment
- Not reported
- Net segment revenue
- ₹378.15 crore
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
Ownership
Who owns it
Promoters hold 71.97% as of Sept 2026; institutions added 0.02 pts since Jun 2026.
- Promoters 71.97%
- Foreign institutions 0.02%
- Domestic institutions 3.34%
- Government 0.00%
- Public 24.67%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 1.02% held
The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Astec LifeSciences Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 67.03% | unchanged | |
| Mutual fund | 2.36% | unchanged |
| 1.82% | unchanged | |
| 1.31% | unchanged | |
| 1.02% | newly disclosed | |
| 0.61% | unchanged | |
| 0.61% | unchanged | |
| 0.61% | unchanged | |
| — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in ASTEC
Filings to Sep 2026
0 new, 0 added, 0 trimmed, 0 sold out — net +0.00 L shares (+0.0%).
- Held by funds
- ₹38 Cr
- 1 schemes
- Biggest holder
- Nippon India Small Cap Fund
- ₹38 Cr · 0.1% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| Nippon India Small Cap Fund Nippon India Mutual Fund | ₹38 Cr | held | Jun '22 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Sep 2026
0 added, 0 trimmed — net 0 shares (+0.0%)
- Funds are sitting on
- -63%
- vs est. average cost
- Held by funds
- ₹38 Cr
- 1 schemes · ≈ 2.3% of the company
Shares held by these funds −27%
Oct '23 5.27 L shares Sep '26
Your own record
Start an Inve Case for Astec LifeSciences Limited
Free account: one company. Everything above stays public.
Write why you follow Astec LifeSciences Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Chemicals companies
- BH
BHARATRASBharat Rasayan Limited - IN
INSECTICIDInsecticides (India) Limited - PA
PAUSHAKLTDPaushak Limited - BH
BHAGERIABhageria Industries Limited - BP
BPAGRIBlue Pearl Agriventures Limited - TI
TIRUMALCHMThirumalai Chemicals Limited - MO
MOLMeghmani Organics Limited - NI
NITTAGELANitta Gelatin India Limited
Learn to analyse Astec LifeSciences Limited
Guides on how to read this kind of business and the numbers that matter.